Both atenolol and propranolol blunt the fibrinolytic response to exercise but not resting fibrinolytic potential.
This randomized, double-blind trial found that tissue plasminogen activator activity increased and plasminogen activator inhibitor-1 activity decreased significantly more with exercise during placebo treatment than during treatment with beta blockade. These results suggest that beta blockade blunts the fibrinolytic response to maximal exercise.
Fernhall
B
B
The Division of Cardiology, The George Washington University Medical Center, Washington, DC, USA.
Szymanski
L M
LM
Gorman
P A
PA
Kamimori
G H
GH
Kessler
C M
CM
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000328:Adult; D000704:Analysis of Variance; D000933:Antifibrinolytic Agents / Q000494:pharmacology*; D001262:Atenolol / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004347:Drug Interactions; D005343:Fibrinolytic Agents / Q000097:blood; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D005082:Physical Exertion / Q000502:physiology*; D010919:Placebos; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D011433:Propranolol / Q000494:pharmacology*; D012146:Rest / Q000502:physiology; D015842:Serine Proteinase Inhibitors / Q000097:blood; D010959:Tissue Plasminogen Activator / Q000037:antagonists & inhibitors* / Q000097:blood
D000319:Adrenergic beta-Antagonists; D000933:Antifibrinolytic Agents; D005343:Fibrinolytic Agents; D010919:Placebos; D017395:Plasminogen Activator Inhibitor 1; D015842:Serine Proteinase Inhibitors; D001262:Atenolol; D011433:Propranolol; D010959:Tissue Plasminogen Activator